MAP2K1 and ARAF

Data Source:
BioGRID (affinity chromatography technology)
HPRD (in vitro)

		MAP2K1	ARAF
Description		mitogen-activated protein kinase kinase 1	A-Raf proto-oncogene, serine/threonine kinase
Image
GO Annotations	Cellular Component	Nucleus Mitochondrion Early Endosome Late Endosome Endoplasmic Reticulum Golgi Apparatus Microtubule Organizing Center Cytosol Plasma Membrane Focal Adhesion	Cellular_component Mitochondrion Cytosol
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity MAP Kinase Kinase Activity Protein Serine/threonine/tyrosine Kinase Activity Protein Tyrosine Kinase Activity MAP-kinase Scaffold Activity Protein Binding ATP Binding Protein C-terminus Binding Protein Serine/threonine Kinase Activator Activity Protein N-terminus Binding Scaffold Protein Binding	Protein Kinase Activity Protein Serine/threonine Kinase Activity MAP Kinase Kinase Kinase Activity Protein Binding ATP Binding Metal Ion Binding Protein Serine Kinase Activity Protein Threonine Kinase Activity
	Biological Process	MAPK Cascade Activation Of MAPK Activity Protein Phosphorylation Chemotaxis Cell Cycle Arrest Signal Transduction Heart Development Negative Regulation Of Cell Population Proliferation Positive Regulation Of Gene Expression Negative Regulation Of Gene Expression Peptidyl-threonine Phosphorylation Peptidyl-tyrosine Phosphorylation Cerebellar Cortex Formation Neuron Differentiation Keratinocyte Differentiation Thyroid Gland Development Regulation Of Stress-activated MAPK Cascade Positive Regulation Of Transcription, DNA-templated Thymus Development Regulation Of Axon Regeneration Cell Motility Positive Regulation Of Axonogenesis Bergmann Glial Cell Differentiation Face Development Trachea Formation Epithelial Cell Proliferation Involved In Lung Morphogenesis Placenta Blood Vessel Development Labyrinthine Layer Development ERK1 And ERK2 Cascade Positive Regulation Of ERK1 And ERK2 Cascade Positive Regulation Of Protein Serine/threonine Kinase Activity Regulation Of Golgi Inheritance Cellular Senescence Positive Regulation Of Production Of MiRNAs Involved In Gene Silencing By MiRNA Regulation Of Early Endosome To Late Endosome Transport	MAPK Cascade Activation Of MAPKK Activity Cellular Protein Modification Process Protein Phosphorylation Regulation Of TOR Signaling Regulation Of Proteasomal Ubiquitin-dependent Protein Catabolic Process Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process
Pathways		MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants	RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants
Drugs		K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide PD-0325901 N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib	ATP
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
GWAS		Prostate cancer ( 29892016) Testicular germ cell tumor ( 28604728 28604732)
Interacting Genes		67 interacting genes: APC ARAF AURKA BANP BAX BIRC6 BMPR1A BRAF BUB1 CASP9 CDH1 CDK5 CDKN2A CPNE1 CPNE4 CTNNA1 EGFR ELK1 EP300 ERBB2 FBXW7 GRB10 HNRNPD HRAS KAT7 KSR1 KSR2 LAMTOR3 MAP3K4 MAP3K8 MAPK1 MAPK14 MAPK3 MAPK8 MAPK8IP3 MBP MLH3 MSH6 MYC ODC1 PAK1 PARVA PDGFRL PEBP1 PEBP4 PIK3CA PLEKHF2 PLK3 PPARG PRKCI PRKCZ PTPRJ RAF1 RPS6KA2 RPS6KA4 SMAD2 SRC STK11 TCP11 TGFBR2 TLR2 TRAF3 TRAF6 TRIB1 UBE2I UBE2L3 WNK1	59 interacting genes: AGTRAP AKT1 ASS1 BAD BECN1 BRAF CCND2 CDK4 CDK6 CDKN2B CHD6 COPS3 CPS1 CSNK2B DIDO1 E2F6 EFEMP1 EPHA2 FGFR4 GLIS2 GNA12 HRAS IRAK2 IRF7 KLHL12 KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K5 MLH1 MYC MYO18A NELFCD NF2 NRAS NUDT14 PBK PDGFRB PIK3CA PIK3R1 PKM PRPF6 RABGGTB RASSF1 RGS12 RRAS RRAS2 SFN STK11 TEKT4P2 TESK1 TIMM44 TIRAP TP53 TSC1 WNK1 YWHAG
Entrez ID		5604	369
HPRD ID		01469	02405
Ensembl ID		ENSG00000169032	ENSG00000078061
Uniprot IDs		A4QPA9 B4DFY5 H3BRW9 Q02750	A0A024R178 P10398 Q96II5
PDB IDs		1S9J 2P55 3DV3 3DY7 3E8N 3EQB 3EQC 3EQD 3EQF 3EQG 3EQH 3EQI 3MBL 3ORN 3OS3 3PP1 3SLS 3V01 3V04 3VVH 3W8Q 3WIG 3ZLS 3ZLW 3ZLX 3ZLY 3ZM4 4AN2 4AN3 4AN9 4ANB 4ARK 4LMN 4MNE 4U7Z 4U80 4U81 5BX0 5EYM 5HZE 5YT3 6NYB 6PP9 6Q0J 6Q0T 6U2G 6X2P 6X2S 6X2X	1WXM 2MSE
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?